Literature DB >> 12845630

Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines.

Sylvie Lantuéjoul1, Bruno Constantin, Harry Drabkin, Christian Brambilla, Joëlle Roche, Elisabeth Brambilla.   

Abstract

Two receptors, neuropilin 1 (NP1) and neuropilin 2 (NP2), bind class 3 semaphorins, axon guidance molecules including SEMA3F, the gene for which was isolated from a 3p21.3 deletion in lung cancer. In addition, they bind VEGF (vascular endothelial growth factor), enhancing the effects of VEGF binding to KDR/Flk-1. Elevated VEGF levels are associated with the loss and cytoplasmic delocalization of SEMA3F in lung cancer, suggesting competition for their NP1 and NP2 receptors. To determine the timing of these events, we compared by immunohistochemistry VEGF, SEMA3F, NP1 and NP2 expression in 50 preneoplastic lesions and 112 lung tumours. In preneoplastic lesions, VEGF increased from low-grade to high-grade dysplasia (p=0.001) whereas SEMA3F levels remained low. NP1 and NP2 levels increased from dysplasia to microinvasive carcinoma (p=0.0001) and correlated with VEGF expression (p=0.04 and 0.0002, respectively). Non-small cell lung carcinoma overexpressed VEGF and NP1 and NP2 significantly more often than neuroendocrine tumours including small cell lung carcinoma. SEMA3F loss or delocalization correlated with advanced tumour stage. Migrating cells overexpressed VEGF, SEMA3F, NP1 and NP2 with cytoplasmic delocalization of NP1 as demonstrated in an in vitro wound assay. These results demonstrate early alteration of the VEGF/SEMA3F/NP pathway in lung cancer progression. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845630     DOI: 10.1002/path.1367

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  43 in total

1.  Association of progressive structural changes in the bronchial epithelium with subepithelial fibrous remodeling: a potential role for hypoxia.

Authors:  Vasiliy V Polosukhin; William E Lawson; Aaron P Milstone; Svetlana M Egunova; Andrey G Kulipanov; Sergey G Tchuvakin; Pierre P Massion; Timothy S Blackwell
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

Authors:  Sophie Kusy; Patrick Nasarre; Daniel Chan; Vincent Potiron; David Meyronet; Robert M Gemmill; Bruno Constantin; Harry A Drabkin; Joëlle Roche
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Authors:  Patrick Nasarre; Robert M Gemmill; Vincent A Potiron; Joëlle Roche; Xian Lu; Anna E Barón; Christopher Korch; Elizabeth Garrett-Mayer; Alessandro Lagana; Philip H Howe; Harry A Drabkin
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 4.  Semaphorin 5A mediated cellular navigation: connecting nervous system and cancer.

Authors:  Abhilasha Purohit; Anguraj Sadanandam; Pavan Myneni; Rakesh K Singh
Journal:  Biochim Biophys Acta       Date:  2014-09-28

Review 5.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

Review 6.  Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?

Authors:  A R L Medford; A B Millar
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

7.  VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Authors:  Asma Boudria; Cherine Abou Faycal; Tao Jia; Stephanie Gout; Michelle Keramidas; Chloé Didier; Nicolas Lemaître; Sandra Manet; Jean-Luc Coll; Anne-Claire Toffart; Denis Moro-Sibilot; Corinne Albiges-Rizo; Véronique Josserand; Eva Faurobert; Christian Brambilla; Elisabeth Brambilla; Sylvie Gazzeri; Beatrice Eymin
Journal:  Oncogene       Date:  2018-09-07       Impact factor: 9.867

8.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

9.  Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues.

Authors:  Christina D Drenberg; Sandra Livingston; Ren Chen; Patricia A Kruk; Santo V Nicosia
Journal:  Obstet Gynecol Int       Date:  2009-11-01

10.  VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.

Authors:  Chang-Han Chen; Jin-Mei Lai; Teh-Ying Chou; Cheng-Yu Chen; Li-Jen Su; Yuan-Chii Lee; Tai-Shan Cheng; Yi-Ren Hong; Chen-Kung Chou; Jacqueline Whang-Peng; Yu-Chung Wu; Chi-Ying F Huang
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.